UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
20.01
-0.71 (-3.43%)
At close: Aug 6, 2025, 4:00 PM
20.20
+0.19 (0.95%)
After-hours: Aug 6, 2025, 7:14 PM EDT

Company Description

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers.

It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution.

The company’s lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC).

It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC.

The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H.

to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

UroGen Pharma Ltd.
UroGen Pharma logo
CountryUnited States
Founded2004
IPO DateMay 4, 2017
IndustryBiotechnology
SectorHealthcare
Employees235
CEOElizabeth Barrett

Contact Details

Address:
400 Alexander Park Drive, 4th Floor
Princeton, New Jersey 08540
United States
Phone646 768 9780
Websiteurogen.com

Stock Details

Ticker SymbolURGN
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001668243
CUSIP NumberM96088105
ISIN NumberIL0011407140
SIC Code2834

Key Executives

NamePosition
Elizabeth A. BarrettPresident, Chief Executive Officer and Director
Christopher Degnan CPAChief Financial Officer
Jason Drew Smith J.D.General Counsel, Chief Compliance Officer and Corporate Secretary
Vincent I. PerroneSenior Director of Investor Relations
Bryon WornsonExecutive Vice President of Talent, Advocacy and Communications
Dr. Marina Konorty Ph.D.Executive Vice President of Research and Development and Technical Operations
Dr. Mark P. Schoenberg M.D.Chief Medical Officer
James Ottinger R.ph.Executive Vice President of Regulatory Affairs and Quality
Michael J. Louie M.D., M.P.H., M.Sc.Executive Vice President of Medical Affairs and Clinical Development
David LinChief Commercial Officer

Latest SEC Filings

DateTypeTitle
Aug 6, 2025SCHEDULE 13GFiling
Aug 5, 2025SCHEDULE 13G/AFiling
Jul 29, 2025SCHEDULE 13G/AFiling
Jul 29, 2025144Filing
Jul 29, 2025144Filing
Jul 16, 2025SCHEDULE 13G/AFiling
Jul 16, 2025ARSFiling
Jul 15, 2025DEF 14AOther definitive proxy statements
Jul 3, 20258-KCurrent Report
Jun 16, 2025SCHEDULE 13GFiling